Molecular neuroimaging is today considered essential for evaluation of novel CNS drugs; it is used to quantify blood-brain barrier permeability, verify interaction with key target and determine the drug dose resulting in 50% occupancy, IC. In spite of this, there has been limited data available to inform on how to optimize study designs. Through simulations, we here evaluate how IC estimation is affected by the (i) range of drug doses administered, (ii) number of subjects included, and (iii) level of noise in the plasma drug concentration measurements. Receptor occupancy is determined from PET distribution volumes using two different methods: the Lassen plot and Likelihood estimation of occupancy (LEO). We also introduce and evaluate a new likelihood-based estimator for direct estimation of IC from PET distribution volumes. For estimation of IC, we find very limited added benefit in scanning individuals who are given drug doses corresponding to less than 40% receptor occupancy. In the range of typical PET sample sizes (5-20 subjects) each extra individual clearly reduces the error of the IC estimate. In all simulations, likelihood-based methods gave more precise IC estimates than the Lassen plot; four times the number of subjects were required for the Lassen plot to reach the same IC precision as LEO.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neuroimage.2022.119620 | DOI Listing |
Anesth Analg
November 2024
Department of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California.
Niels Lassen's seminal 1959 cerebral autoregulation plot, a cornerstone in understanding the relationship between mean arterial pressure (MAP) and cerebral blood flow (CBF), was based on preexisting literature. However, this work has faced criticism for selective data presentation, leading to inaccurate interpretation. This review revisits and validates Lassen's original plot using contemporary data published since 2000.
View Article and Find Full Text PDFTher Adv Med Oncol
October 2024
Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Background: Dysregulated pathways in cancer may be hub addicted. Identifying these dysregulated networks for targeting might lead to novel therapeutic options.
Objective: Considering the hypothesis that central hubs are associated with increased lethality, identifying key hub targets within central networks could lead to the development of novel drugs with improved efficacy in advanced metastatic solid tumors.
EJNMMI Res
June 2024
Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Background: In preclinical studies, the positron emission tomography (PET) imaging with [C]UCB-A provided promising results for imaging synaptic vesicle protein 2A (SV2A) as a proxy for synaptic density. This paper reports the first-in-human [C]UCB-A PET study to characterise its kinetics in healthy subjects and further evaluate SV2A-specific binding.
Results: Twelve healthy subjects underwent 90-min baseline [C]UCB-A scans with PET/MRI, with two subjects participating in an additional blocking scan with the same scanning procedure after a single dose of levetiracetam (1500 mg).
Eur J Nucl Med Mol Imaging
September 2024
Epilepsy Clinic, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, Copenhagen O, 2100, Denmark.
EJNMMI Phys
December 2023
Department of Biomedical Engineering, Yale University, New Haven, CT, USA.
Background: Drug occupancy studies with positron emission tomography imaging are used routinely in early phase drug development trials. Recently, our group introduced the Lassen Plot Filter, an extended version of the standard Lassen plot to estimate voxel-level occupancy images. Occupancy images can be used to create an EC image by applying an E model at each voxel.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!